<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29695967</article-id><article-id pub-id-type="pmc">5904201</article-id><article-id pub-id-type="doi">10.3389/fphar.2018.00352</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title>Influence of <italic>APOA5</italic> Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hua</surname><given-names>Sha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/498542/overview"/></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Chuanxiang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/544511/overview"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Guanghua</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jianrong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Cardiology, Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiao Tong University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Pathology, Affiliated Hospital of Weifang Medical University</institution>, <addr-line>Weifang</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Comprehensive Laboratory, Third Affiliated Hospital of Soochow University</institution>, <addr-line>Changzhou</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Section of Clinical Chemistry and Pharmacology, Institute of Laboratory Medicine, Lund University</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Marcelo Rizzatti Luizon, Universidade Federal de Minas Gerais, Brazil</p></fn><fn fn-type="edited-by"><p>Reviewed by: Stella Trompet, Leiden University Medical Center, Netherlands; Vanessa Fontana, University of Liverpool, United Kingdom</p></fn><corresp id="c001">*Correspondence: Guanghua Luo, <email>shineroar@163.com</email> Jianrong Zhao, <email>drzjr@126.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>352</elocation-id><history><date date-type="received"><day>11</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Hua, Ma, Zhang, Li, Wu, Xu, Luo and Zhao.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Hua, Ma, Zhang, Li, Wu, Xu, Luo and Zhao</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is <italic>APOA5</italic>, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored <italic>APOA5</italic>-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5&#x02013;10 mg/day), atorvastatin (10&#x02013;20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the <italic>APOA5</italic> promoter SNP rs662799 (-1131T &#x0003e; C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL cholesterol were influenced by the <italic>APOA5</italic> genotype in all three treatment groups. By contrast, changes in HDL cholesterol, and triglycerides were only affected by the <italic>APOA5</italic> genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results suggest that future studies may need to consider stratifying subjects not only by genetic background but also by prescribed statin type.</p></abstract><kwd-group><kwd><italic>APOA5</italic> genotype</kwd><kwd>statins</kwd><kwd>triglycerides</kwd><kwd>LDL cholesterol</kwd><kwd>dyslipidemia</kwd></kwd-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="55"/><page-count count="8"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Statins are the most prescribed class of drugs worldwide for prevention of various cardiovascular diseases. However, about one third of patients do not respond well to this therapy with respect to the lipid-lowering effect, suggesting that pharmacogenomics (<xref rid="B46" ref-type="bibr">Postmus et al., 2014</xref>) or other environmental factors such as diet (<xref rid="B28" ref-type="bibr">Jenkins et al., 2005</xref>) or the gut microbiome (<xref rid="B30" ref-type="bibr">Kaddurah-Daouk et al., 2011</xref>) may play substantial roles. To date, genome-wide association studies have identified at least 39 genes that are associated with statin treatment efficacy (<xref rid="B19" ref-type="bibr">Gryn and Hegele, 2014</xref>). Most of these genes are involved in either the direct pharmacokinetic handling of statins or in lipid metabolism pathways especially those involving cholesterol, the main target of statin therapy (<xref rid="B37" ref-type="bibr">Mangravite et al., 2006</xref>). However, accumulating evidence indicates that statins can also lower levels of triglycerides, potentially through altering degradation of apolipoprotein B (ApoB) and related very low-density lipoprotein (VLDL) balance, although the precise mechanism remains unclear (<xref rid="B17" ref-type="bibr">Ginsberg et al., 1987</xref>; <xref rid="B1" ref-type="bibr">Arad et al., 1992</xref>; <xref rid="B16" ref-type="bibr">Ginsberg, 1998</xref>).</p><p>One gene of particular interest within this context is <italic>APOA5</italic> (<xref rid="B21" ref-type="bibr">Guardiola and Ribalta, 2017</xref>), which was identified in 2001 (<xref rid="B45" ref-type="bibr">Pennacchio et al., 2001</xref>; <xref rid="B55" ref-type="bibr">van der Vliet et al., 2001</xref>) and has been associated with high inter-individual variations of serum triglycerides in all reported populations (<xref rid="B5" ref-type="bibr">Baum et al., 2003</xref>; <xref rid="B34" ref-type="bibr">Lai et al., 2004</xref>; <xref rid="B26" ref-type="bibr">Hubacek et al., 2008</xref>; <xref rid="B43" ref-type="bibr">Ouatou et al., 2014</xref>; <xref rid="B51" ref-type="bibr">Son et al., 2015</xref>). Accumulating evidence also suggests that polymorphisms in this gene confers risk for cardiovascular disease (<xref rid="B34" ref-type="bibr">Lai et al., 2004</xref>; <xref rid="B22" ref-type="bibr">Han et al., 2017</xref>) and myocardial infarction (<xref rid="B14" ref-type="bibr">Do et al., 2015</xref>). Two of the most characterized <italic>APOA5</italic> SNPs are rs662799 (-1131T &#x0003e; C) and rs3135506 (56C &#x0003e; G) (<xref rid="B27" ref-type="bibr">Hubacek et al., 2004</xref>; <xref rid="B35" ref-type="bibr">Lim et al., 2014</xref>; <xref rid="B11" ref-type="bibr">Chen et al., 2018</xref>; <xref rid="B32" ref-type="bibr">Kim et al., 2018</xref>). Of note, rs662799 is more common in the Asian population (26&#x02013;40%) than in Caucasians (&#x0223c;8%) (<xref rid="B5" ref-type="bibr">Baum et al., 2003</xref>; <xref rid="B32" ref-type="bibr">Kim et al., 2018</xref>). According to one estimation, this SNP alone can contribute to 6.2% of the genetic component of hypertriglyceridemia (<xref rid="B23" ref-type="bibr">Hegele, 2009</xref>).</p><p>Although it has previously been suggested that there is a link between <italic>APOA5</italic> and statin treatment (<xref rid="B7" ref-type="bibr">Brautbar et al., 2011</xref>; <xref rid="B42" ref-type="bibr">O&#x02019;Brien et al., 2015</xref>), neither the type nor the dose of statins was taken into consideration in these earlier studies; it is important to note that statins differ in terms of their pharmacodynamic and pharmacogenetic properties (<xref rid="B33" ref-type="bibr">Kivisto et al., 2004</xref>; <xref rid="B49" ref-type="bibr">Schachter, 2005</xref>) and potency (<xref rid="B44" ref-type="bibr">Palmer et al., 2013</xref>; <xref rid="B2" ref-type="bibr">Arshad, 2014</xref>; <xref rid="B31" ref-type="bibr">Karlson et al., 2016</xref>). Another retrospective study did not observe an effect of statin type when investigating the interaction between the rs662799 variants and statins (<xref rid="B25" ref-type="bibr">Hubacek et al., 2009</xref>); however, this study did not include rosuvastatin, which is often considered to be a better treatment choice (<xref rid="B50" ref-type="bibr">Scott et al., 2004</xref>; <xref rid="B39" ref-type="bibr">McKenney, 2005</xref>; <xref rid="B49" ref-type="bibr">Schachter, 2005</xref>).</p><p>Here, we performed a pilot study to explore <italic>APOA5</italic>-statin interactions in 195 Chinese subjects randomized to rosuvastatin, atorvastatin, or simvastatin therapy for 12 weeks. To address whether the reduction in cholesterol and apolipoprotein levels of three types of statins differ between subjects with the same <italic>APOA5</italic> genetic background, we genotyped the <italic>APOA5</italic> rs662799 SNP and measured the fasting plasma concentrations of triglycerides, cholesterols, FFAs, and four apolipoproteins both before and after statin treatments.</p></sec><sec sec-type="materials|methods" id="s1"><title>Materials and Methods</title><sec><title>Study Subjects and Study Design</title><p>Between 2015 and 2016, we screened 240 patients with treatment-naive dyslipidemia at Shanghai Ruijin Hospital Luwan Branch (affiliated to Shanghai Jiao Tong University) and recruited 195 to this study (Supplementary Figure <xref ref-type="supplementary-material" rid="SM3">S1</xref>). The inclusion criteria were: (i) preregistered with our medial examination center for annual routine heath screening; (ii) aged 18 years or older; (iii) newly diagnosed with dyslipidemia and/or increased risk of atherosclerotic cardiovascular diseases and recommended to receive statins according to the 2013 American College of Cardiology and the American Heart Association Blood Cholesterol Guidelines (<xref rid="B52" ref-type="bibr">Stone et al., 2014</xref>); (iv) capable of understanding the scope and potential consequences of this study. The exclusion criteria were: (i) major systematic diseases such as malignancy; (ii) heart failure experience; (iii) dramatic weight loss and medication (especially antibiotics) 2 months before recruitment except antihypertensive therapy; (iv) acute illnesses. All patients newly diagnosed with dyslipidemia were encouraged to adopt lifestyle changes first for 2&#x02013;4 months before moderate statin treatment; thus, only those who failed to achieve the therapeutic goal (mostly due to poor adherence to the dietary and/or exercise recommendations) were considered as eligible for this study.</p><p>The 195 subjects were then randomly divided into three treatment arms to receive rosuvastatin (5&#x02013;10 mg/day), atorvastatin (10&#x02013;20 mg/day), or simvastatin (40 mg/day) for 12 weeks (<italic>n</italic> = 65 for each treatment arm). To achieve comparable clinical efficacies in response to the three statins, the different statin doses were selected based on both clinical practice and evidence suggesting that each rosuvastatin dose is equivalent to 3&#x02013;3.5 times of atorvastatin and 7&#x02013;8 times of simvastatin (at least in terms of cholesterol reduction) (<xref rid="B25" ref-type="bibr">Hubacek et al., 2009</xref>). Follow-up evaluations were performed every 2 weeks and no side effects or poor adherence was reported.</p><p>Written informed consent was obtained from all the study participants. This study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by Ethics Committee of Shanghai Ruijin Hospital Luwan Branch. Complete clinical trial registration is deposited at chictr.org.cn (ChiCTR-RRC-16010131).</p></sec><sec><title>Laboratory Analyses</title><p>Fasting plasma concentrations of triglycerides, total cholesterol, HDL cholesterol (HDLc), LDL cholesterol (LDLc), FFAs, three different apolipoproteins (ApoA1, ApoB-100, and ApoE), and Lp(a) were measured by enzymatic methods using a Beckman Coulter Chemistry Analyzer AU5800 Series (United States) at both baseline and 12 weeks after treatments.</p><p>After the randomization and initiation of treatments, DNA was isolated using the TIANamp Blood DNA kit (purchased from Tiangen, Beijing, China) and individual <italic>APOA5</italic> variants (-1131T &#x0003e; C &#x02013; rs662799) were genotyped using a base-quenched probe method combined with polymerase chain reaction (PCR) as described before (<xref rid="B36" ref-type="bibr">Luo et al., 2009</xref>). In brief, a 19-nt probe (5&#x02032;-GGCAAATCTCACTTTCGCT-3&#x02032;) containing the targeted SNP site was first conjugated with 6-carboxyfluorescein and then hybridized to its complementary target sequence from PCR amplification. An analytical melting program that involves heating the amplicon/probe heteroduplex will produce different fluorescence curves depending on the genotypes of rs662799. Both the probe and primers (forward: 5&#x02032;-AGGAGTGTGGTAGAAAGACCTGTTG-3&#x02032;; reverse: 5&#x02032;-AACTACCCAGAGTCACTGTGTCCC-3&#x02032;) used were synthesized by Sangon (Shanghai, China).</p></sec><sec><title>Statistical Analysis</title><p>Statistical differences between groups were estimated by Wilcox rank-sum test (between two groups), Kruskal&#x02013;Wallis test (among three groups) for continuous variables or by Chi-square test for categorical variables. T/C and C/C subjects were pooled as C allele carriers for all statistical analyses to increase the power. Both the percentage and absolute changes of LDLc, HDLc and triglycerides in response to each statin were further adjusted for age, sex, and BMI by using linear regression models. In cases of models based on absolute changes, the baseline values were also entered as covariates. However, statin doses were not considered since similar doses of statin were prescribed for all subjects within the same treatment arm. A backward variable selection procedure was performed using R function &#x02018;step&#x02019; based on the Akaike information criterion (AIC). <italic>APOA5</italic>-statin interaction was further explored by adding an interaction term into the models. Associations between apolipoproteins and concentrations of LDLc and HDLc were measured by Spearman&#x02019;s rank correlation analysis. Hardy&#x02013;Weinberg Equilibrium was accessed by exact test based on R package &#x0201c;HardyWeinberg&#x0201d; (<xref rid="B18" ref-type="bibr">Graffelman, 2015</xref>). Raw P values were adjusted by the Benjamini&#x02013;Hochberg method (<xref rid="B6" ref-type="bibr">Benjamini and Hochberg, 1995</xref>) with a false discovery rate of 5%. A power of 99.98% was obtained using pwr package (<xref rid="B10" ref-type="bibr">Champely, 2015</xref>) for this study based on 65 patients (sample size for each treatment arm) with paired design, 5% significance, and an estimated effect size of 0.7 (i.e., effective in 70% of the patients) for statins to reduce LDL cholesterol (<xref rid="B12" ref-type="bibr">Cholesterol Treatment Trialists (CTT) Collaborators, 2012</xref>; <xref rid="B48" ref-type="bibr">Ridker et al., 2016</xref>). All statistical tests and data visualizations as well as the stratified randomization process by considering BMI as covariate were performed under the R environment (<xref rid="B47" ref-type="bibr">R Development Core Team, 2015</xref>).</p></sec></sec><sec><title>Results</title><sec><title>Baseline Characteristics</title><p>The minor C allele frequency of <italic>APOA5</italic> rs662799 SNP in our cohort was 30%, consistent with other reports based on larger Chinese cohorts (<xref rid="B5" ref-type="bibr">Baum et al., 2003</xref>; <xref rid="B29" ref-type="bibr">Jiang et al., 2010</xref>); the genotype frequency of <italic>APOA5</italic> was in agreement with Hardy&#x02013;Weinberg Equilibrium (<italic>n</italic> = 13, 91 and 91 for C/C, T/C, and T/T allele carriers, respectively; <italic>P</italic> = 0.171). With the exception of ApoE, there were no significant baseline differences between the treatment arms, including the frequencies of the three <italic>APOA5</italic> genotypes (<italic>P</italic> = 0.597) (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). These data suggest that the treatment groups are in general homogeneous and this study design is suitable for addressing the relationship between <italic>APOA5</italic> variations and the clinical responses of three statins.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics summarized by statin treatment and <italic>APOA5</italic> genotypes, respectively.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" colspan="3" rowspan="1">Statin treatment<sup>a</sup><hr/></th><td valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" colspan="3" rowspan="1"><italic>APOA5</italic> genotype<sup>a</sup><hr/></th><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Atorvastatin</th><th valign="top" align="center" rowspan="1" colspan="1">Rosuvastatin</th><th valign="top" align="center" rowspan="1" colspan="1">Simvastatin</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic><sup>b</sup></th><th valign="top" align="center" rowspan="1" colspan="1">C/C</th><th valign="top" align="center" rowspan="1" colspan="1">T/C</th><th valign="top" align="center" rowspan="1" colspan="1">T/T</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic><sup>e</sup></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">4/32/29<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">5/25/35<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">4/34/27<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.597<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">91</td><td valign="top" align="center" rowspan="1" colspan="1">91</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male (%)</td><td valign="top" align="center" rowspan="1" colspan="1">53.8</td><td valign="top" align="center" rowspan="1" colspan="1">44.6</td><td valign="top" align="center" rowspan="1" colspan="1">49.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.575<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">69.2</td><td valign="top" align="center" rowspan="1" colspan="1">41.8</td><td valign="top" align="center" rowspan="1" colspan="1">53.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.288<sup>c</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">74.9 &#x000b1; 10.5</td><td valign="top" align="center" rowspan="1" colspan="1">75.0 &#x000b1; 11.8</td><td valign="top" align="center" rowspan="1" colspan="1">69.8 &#x000b1; 17.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.344</td><td valign="top" align="center" rowspan="1" colspan="1">72.2 &#x000b1; 13.9</td><td valign="top" align="center" rowspan="1" colspan="1">72.9 &#x000b1; 12.7</td><td valign="top" align="center" rowspan="1" colspan="1">73.7 &#x000b1; 14.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.420</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">23.5 &#x000b1; 3.2</td><td valign="top" align="center" rowspan="1" colspan="1">23.5 &#x000b1; 3.3</td><td valign="top" align="center" rowspan="1" colspan="1">23.4 &#x000b1; 3.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.938</td><td valign="top" align="center" rowspan="1" colspan="1">24.1 &#x000b1; 2.7</td><td valign="top" align="center" rowspan="1" colspan="1">23.4 &#x000b1; 3.7</td><td valign="top" align="center" rowspan="1" colspan="1">23.3 &#x000b1; 2.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.662</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tc (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">193.1 &#x000b1; 49.5</td><td valign="top" align="center" rowspan="1" colspan="1">180.2 &#x000b1; 40.6</td><td valign="top" align="center" rowspan="1" colspan="1">186.7 &#x000b1; 49.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.306</td><td valign="top" align="center" rowspan="1" colspan="1">194.1 &#x000b1; 28.2</td><td valign="top" align="center" rowspan="1" colspan="1">191.6 &#x000b1; 47.3</td><td valign="top" align="center" rowspan="1" colspan="1">180.7 &#x000b1; 47.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tg (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">180.1 &#x000b1; 110.5</td><td valign="top" align="center" rowspan="1" colspan="1">162.6 &#x000b1; 102.6</td><td valign="top" align="center" rowspan="1" colspan="1">181.9 &#x000b1; 138.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.482</td><td valign="top" align="center" rowspan="1" colspan="1">266.9 &#x000b1; 151.2</td><td valign="top" align="center" rowspan="1" colspan="1">183.3 &#x000b1; 117.8</td><td valign="top" align="center" rowspan="1" colspan="1">153.4 &#x000b1; 105.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDLc (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">42.1 &#x000b1; 9.9</td><td valign="top" align="center" rowspan="1" colspan="1">44.1 &#x000b1; 10.4</td><td valign="top" align="center" rowspan="1" colspan="1">44.6 &#x000b1; 11.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.458</td><td valign="top" align="center" rowspan="1" colspan="1">41.1 &#x000b1; 11.3</td><td valign="top" align="center" rowspan="1" colspan="1">43.4 &#x000b1; 10.7</td><td valign="top" align="center" rowspan="1" colspan="1">44.1 &#x000b1; 10.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.513</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDLc (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">132.2 &#x000b1; 42.9</td><td valign="top" align="center" rowspan="1" colspan="1">125.8 &#x000b1; 34.8</td><td valign="top" align="center" rowspan="1" colspan="1">125.7 &#x000b1; 41.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.780</td><td valign="top" align="center" rowspan="1" colspan="1">145.4 &#x000b1; 35.0</td><td valign="top" align="center" rowspan="1" colspan="1">133.1 &#x000b1; 41.3</td><td valign="top" align="center" rowspan="1" colspan="1">120.1 &#x000b1; 37.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ApoA1 (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">114.4 &#x000b1; 20.6</td><td valign="top" align="center" rowspan="1" colspan="1">119.1 &#x000b1; 23.3</td><td valign="top" align="center" rowspan="1" colspan="1">116.9 &#x000b1; 20.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.515</td><td valign="top" align="center" rowspan="1" colspan="1">113.4 &#x000b1; 8.8</td><td valign="top" align="center" rowspan="1" colspan="1">116.7 &#x000b1; 23.2</td><td valign="top" align="center" rowspan="1" colspan="1">117.3 &#x000b1; 20.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.708</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ApoB-100 (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">86.3 &#x000b1; 31.2</td><td valign="top" align="center" rowspan="1" colspan="1">86.5 &#x000b1; 25.0</td><td valign="top" align="center" rowspan="1" colspan="1">94.1 &#x000b1; 29.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.181</td><td valign="top" align="center" rowspan="1" colspan="1">99.5 &#x000b1; 22.2</td><td valign="top" align="center" rowspan="1" colspan="1">91.0 &#x000b1; 29.3</td><td valign="top" align="center" rowspan="1" colspan="1">85.4 &#x000b1; 28.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.145</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ApoE (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 &#x000b1; 1.5</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 &#x000b1; 1.0</td><td valign="top" align="center" rowspan="1" colspan="1">4.5 &#x000b1; 1.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.019</td><td valign="top" align="center" rowspan="1" colspan="1">4.7 &#x000b1; 1.7</td><td valign="top" align="center" rowspan="1" colspan="1">4.3 &#x000b1; 1.3</td><td valign="top" align="center" rowspan="1" colspan="1">4.2 &#x000b1; 1.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.382</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FFA (mmol/l)</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.780</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.052</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lp(a) (mg/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">17.5 &#x000b1; 17.0</td><td valign="top" align="center" rowspan="1" colspan="1">18.0 &#x000b1; 15.4</td><td valign="top" align="center" rowspan="1" colspan="1">19.8 &#x000b1; 17.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.916</td><td valign="top" align="center" rowspan="1" colspan="1">25.3 &#x000b1; 25.2</td><td valign="top" align="center" rowspan="1" colspan="1">17.5 &#x000b1; 12.6</td><td valign="top" align="center" rowspan="1" colspan="1">18.4 &#x000b1; 18.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.575</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Type 2 diabetes (%)</td><td valign="top" align="center" rowspan="1" colspan="1">43.1</td><td valign="top" align="center" rowspan="1" colspan="1">40.0</td><td valign="top" align="center" rowspan="1" colspan="1">32.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.430<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">53.8</td><td valign="top" align="center" rowspan="1" colspan="1">38.5</td><td valign="top" align="center" rowspan="1" colspan="1">36.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.658<sup>c</sup></td></tr></tbody></table><table-wrap-foot><attrib><sup>a</sup><italic>Continuous variables are expressed as mean &#x000b1; standard deviations (sd); <sup><italic>b</italic></sup><italic>P</italic>-values were estimated by Krukskal&#x02013;Wallis test for continuous variables; <sup><italic>c</italic></sup><italic>P</italic>-values were estimated by Chi-square test for categorical variables; <sup><italic>d</italic></sup>Sample sizes for individuals genotyped as C/C, T/C and T/T, respectively; <sup><italic>e</italic></sup><italic>P</italic>-values were estimated by Wilcox rank-sum test for continuous variables (C/C and T/C were pooled as one group in this case)</italic>.</attrib></table-wrap-foot></table-wrap><p>When stratifying the subjects by genotype, the C allele carriers (including both C/C and T/C) had significantly higher plasma triglycerides than T/T carriers at baseline (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>), in agreement with previous studies (<xref rid="B5" ref-type="bibr">Baum et al., 2003</xref>; <xref rid="B34" ref-type="bibr">Lai et al., 2004</xref>; <xref rid="B29" ref-type="bibr">Jiang et al., 2010</xref>). We also noted that subjects with the C allele carriers had higher LDLc than T/T carriers at baseline (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>).</p></sec><sec><title>Rosuvastatin-Induced Changes in HDLc and Triglycerides Are Not Associated With <italic>APOA5</italic> Genotype</title><p>We next compared the clinical efficacies of the statins (in terms of changes of cholesterol, triglyceride, and apolipoprotein). As expected, all three statins promoted significant reductions in total cholesterol, ApoB, LDLc, ApoE, and triglycerides and significant increases in ApoA1 and HDLc (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>). However, there were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers after adjusting for multiple testing (false discovery rate 5%), confirming that the response to 5&#x02013;10 mg of rosuvastatin is similar to that of 10&#x02013;20 mg atorvastatin and 40 mg of simvastatin as suggested previously (<xref rid="B25" ref-type="bibr">Hubacek et al., 2009</xref>). In agreement, results from a meta-analysis (<xref rid="B31" ref-type="bibr">Karlson et al., 2016</xref>), comparative pharmacology (<xref rid="B40" ref-type="bibr">McTaggart, 2003</xref>) and the MERCURY II clinical trial (<xref rid="B3" ref-type="bibr">Ballantyne et al., 2006</xref>) have all shown that rosuvastatin is more potent than the other statins and thus lower doses can be used to achieve equivalent responses.</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p><italic>APOA5</italic>-statin interactions. <bold>(A)</bold> Box plots (with median) showing percentage changes in the indicated biomarkers after treatment with rosuvastatin (5&#x02013;10 mg/day), atorvastatin (10&#x02013;20 mg/day) or simvastatin (40 mg/day). <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup><italic>P</italic> &#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup><italic>P</italic> &#x0003c; 0.001 versus before treatment. (Wilcoxon signed-rank test) <bold>(B&#x02013;E)</bold> Box plots (with median) showing percentage changes in total cholesterol (Tc) <bold>(B)</bold>, LDLc <bold>(C)</bold>, HDLc <bold>(D)</bold>, and triglycerides (Tg) <bold>(E)</bold> in response to each statin in subjects divided by <italic>APOA5</italic> rs662799 genotypes. Sample sizes for each subgroup are given on top of <bold>(B&#x02013;E)</bold>. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup><italic>P</italic> &#x0003c; 0.01 (Wilcoxon rank-sum test; C/C and T/T subjects were pooled together for statistical testing).</p></caption><graphic xlink:href="fphar-09-00352-g001"/></fig><p>To determine how <italic>APOA5</italic> variations were associated with the clinical responses of the three statins, we investigated how changes in the biomarker concentrations in response to each statin varied among the three <italic>APOA5</italic> genotypes (<bold>Figures <xref ref-type="fig" rid="F1">1B</xref>&#x02013;<xref ref-type="fig" rid="F1">E</xref></bold> and Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). No significant differences were observed among three <italic>APOA5</italic> variants in terms of the percentage changes of total cholesterol (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>), apolipoproteins, FFA, and Lp(a) (data not shown) in response to any of the three statins. However, compared with the C allele carriers, patients homozygous for the major T allele exhibited: (1) lower baseline LDLc levels independent of statin type (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>); (2) significantly larger statin-induced LDLc reductions, independent of statin type (<bold>Figure <xref ref-type="fig" rid="F1">1C</xref></bold>); and (3) more pronounced statin-induced changes in HDLc and triglycerides upon atorvastatin or simvastatin treatment (<bold>Figures <xref ref-type="fig" rid="F1">1D,E</xref></bold>). By contrast, rosuvastatin-induced changes in HDLc and triglycerides showed little variation among the three <italic>APOA5</italic> variants (<bold>Figures <xref ref-type="fig" rid="F1">1D,E</xref></bold>). This finding suggesting that statin&#x02013;<italic>APOA5</italic> interactions may also depend on the statin type was further supported by linear regression analyses by adding the treatment and genotype interaction term (<bold>Table <xref ref-type="table" rid="T2">2</xref></bold>); the results were still valid after adjusting for age, sex, and BMI (<bold>Table <xref ref-type="table" rid="T2">2</xref></bold>). We obtained similar results when using the absolute changes of each biomarker additionally adjusted for the baseline biomarker values (Supplementary Table <xref ref-type="supplementary-material" rid="SM2">S2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Percentage changes of LDLc, HDLc, and triglycerides in response to each statin treatment adjusted for sex, age, and BMI using linear regression models.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Initial models</th><th valign="top" align="left" rowspan="1" colspan="1">Treatment</th><th valign="top" align="left" rowspan="1" colspan="1">Final models</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; sex+age+BMI+genotype</td><td valign="top" align="left" rowspan="1" colspan="1">Atorvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.003</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rosuvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; sex+BMI+genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.015</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.046</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Simvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; sex+age+genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.02</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; sex+age+BMI+genotype+treatment+interaction</td><td valign="top" align="left" rowspan="1" colspan="1">Interaction</td><td valign="top" align="left" rowspan="1" colspan="1">%LDLc &#x0223c; age+genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">%HDLc &#x0223c; sex+age+BMI+genotype</td><td valign="top" align="left" rowspan="1" colspan="1">Atorvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%HDLc &#x0223c; age+genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.0004</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.002</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rosuvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">Not significant</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Simvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%HDLc &#x0223c; genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.002</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">%HDLc &#x0223c; sex+age+BMI+genotype+treatment+interaction</td><td valign="top" align="left" rowspan="1" colspan="1">Interaction</td><td valign="top" align="left" rowspan="1" colspan="1">%HDLc &#x0223c; age+genotype+treatment+interaction</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; sex+age+BMI+genotype</td><td valign="top" align="left" rowspan="1" colspan="1">Atorvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.01</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rosuvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; BMI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Simvastatin</td><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; genotype</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic><sub>model</sub> = 0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic><sub>genotype</sub> = 0.006</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; sex+age+BMI+genotype+treatment+interaction</td><td valign="top" align="left" rowspan="1" colspan="1">Interaction</td><td valign="top" align="left" rowspan="1" colspan="1">%Tg &#x0223c; BMI+genotype+treatment+interaction</td></tr></tbody></table></table-wrap></sec><sec><title>Statin&#x02013;<italic>APOA5</italic> Interactions Altered the Correlations Between Apolipoproteins and LDLc/HDLc</title><p>Although most therapies to reduce cardiovascular disease risk currently focus on reduction of LDLc and triglycerides, atherogenic proteins such as ApoB have also been suggested to have great predictive value (<xref rid="B4" ref-type="bibr">Ballantyne et al., 2008</xref>). Accordingly, the American Diabetes Association and the American College of Cardiology Foundation recommend that therapy for patients with high cardiovascular disease risk should aim to lower ApoB concentrations to below 90 mg/dl in addition to reducing LDLc levels (<xref rid="B8" ref-type="bibr">Brunzell et al., 2008</xref>). To address whether the well-known associations between ApoB and LDLc both before and after statin treatments (<xref rid="B4" ref-type="bibr">Ballantyne et al., 2008</xref>) differ among patients with different <italic>APOA5</italic> genotypes, we additionally analyzed ApoB&#x02013;LDLc correlations within each <italic>APOA5</italic> SNP subgroup. For C allele carriers, the Spearman correlation coefficients between ApoB and LDLc were comparable before and after treatment [&#x003c1; = 0.55 (<italic>P</italic> &#x0003c; 0.001) and 0.50 (<italic>P</italic> &#x0003c; 0.001), respectively] (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>). By contrast, in T/T homozygotes, the ApoB&#x02013;LDLc correlation reduced dramatically after treatment [from 0.78 (<italic>P</italic> &#x0003c; 0.001) before treatment to 0.44 (<italic>P</italic> &#x0003c; 0.001)], indicating that the statin-induced reduction of ApoB in absolute values was much smaller than the statin-induced reduction of LDLc in these patients. Thus, further treatment to reduce the levels of ApoB even after achieving recommended LDLc reductions could be beneficial in T/T carriers. Similar observations were found between ApoA1 and HDLc (Supplementary Figure <xref ref-type="supplementary-material" rid="SM4">S2</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p><bold>|</bold> Both <italic>APOA5</italic> and statin alter the ApoB&#x02013;LDLc correlations. Correlations between ApoB and LDLc before <bold>(A)</bold> and after <bold>(B)</bold> statin treatment in subjects with <italic>APOA5</italic> rs662799 C or T/T allele.</p></caption><graphic xlink:href="fphar-09-00352-g002"/></fig></sec></sec><sec><title>Discussion</title><p>Our pilot study revealed that rosuvastatin achieved comparable improvements in all biomarkers examined despite the fact that it was prescribed at a much lower dose than atorvastatin and simvastatin. We further demonstrated that the reduction of LDLc was strongly affected by <italic>APOA5</italic> independent of the statin type prescribed. In contrast, the percentage changes of HDLc and triglycerides were less affected by <italic>APOA5</italic> variants in the rosuvastatin group than in the other two treatment arms.</p><p>Our findings about the strong <italic>APOA5</italic>-LDLc interactions are consistent with observations in a larger cohort (<xref rid="B34" ref-type="bibr">Lai et al., 2004</xref>) but not with an earlier study involving only Chinese men (<xref rid="B5" ref-type="bibr">Baum et al., 2003</xref>). It is not clear how <italic>APOA5</italic> variants affect LDLc as ApoA5 has only been detected on HDL and VLDL and not on LDL particles (<xref rid="B3" ref-type="bibr">Ballantyne et al., 2006</xref>). However, ApoA5 has been shown to directly interact with members of the LDL-receptor family (<xref rid="B41" ref-type="bibr">Nilsson et al., 2007</xref>). In addition, an earlier study has shown a significant association between the <italic>APOA5</italic> rs662799 SNP and increased risk of early-onset myocardial infarction even after adjusting for triglycerides (<xref rid="B13" ref-type="bibr">De Caterina et al., 2011</xref>), providing further evidence that this SNP may simultaneously affect other atherogenic lipids such as LDLc. It is also possible that this SNP is in complete linkage disequilibrium with other polymorphism(s) that can explain the observed LDLc levels.</p><p>In contrast to LDLc, we observed significant <italic>APOA5</italic>-HDLc and -triglyceride interactions in the atorvastatin and simvastatin groups but not in the rosuvastatin group. Possible explanations for these different treatment responses according to genotype include the following: (1) the hydrophilic rosuvastatin is largely excreted unchanged (<xref rid="B38" ref-type="bibr">Martin et al., 2003</xref>) whereas the other two lipophilic statins undergo substantial metabolism by the CYP450 pathways and thus are potentially more affected by gene polymorphisms (<xref rid="B33" ref-type="bibr">Kivisto et al., 2004</xref>; <xref rid="B49" ref-type="bibr">Schachter, 2005</xref>); (2) rosuvastatin differs from the other statins by its stronger binding to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, lower systemic bioavailability, longer elimination half-life (<xref rid="B40" ref-type="bibr">McTaggart, 2003</xref>) and greater hepatoselectivity (<xref rid="B49" ref-type="bibr">Schachter, 2005</xref>); (3) an involvement of other apolipoproteins as <italic>APOA5</italic> variants have been associated with modulations of lipoprotein subclasses especially VLDL and HDL; however, no link between <italic>APOA5</italic> and ApoB has been reported (<xref rid="B54" ref-type="bibr">Talmud et al., 2004</xref>; <xref rid="B20" ref-type="bibr">Guardiola et al., 2015</xref>; <xref rid="B21" ref-type="bibr">Guardiola and Ribalta, 2017</xref>); and (4) an involvement of other SNPs, such as the <italic>APOA5</italic> variant rs2266788, that are in strong linkage disequilibrium with rs662799 (<xref rid="B9" ref-type="bibr">Caussy et al., 2014</xref>). To fully understand how <italic>APOA5</italic> affects statin treatments, in-depth characterizations of its functional role are still needed.</p><p>Our findings in this pilot study are limited by both the sample size and targeted genotyping of a single SNP. A further limitation is that we did not measure ApoA5 protein levels; however, previous studies have suggested that the <italic>APOA5</italic> SNP rs662799 studied here is not associated with <italic>APOA5</italic> mRNA expression levels or with circulating concentrations of this apolipoprotein (<xref rid="B53" ref-type="bibr">Talmud et al., 2006</xref>; <xref rid="B24" ref-type="bibr">Henneman et al., 2007</xref>; <xref rid="B32" ref-type="bibr">Kim et al., 2018</xref>). Some of the participants did not respond to statins, and we cannot exclude the possibility that poor adherence to their prescribed treatment played a role. However, good adherence to statin treatment was reported.</p></sec><sec><title>Conclusion</title><p>In summary, our results show that low-dose rosuvastatin achieves improvements in clinical responses that are comparable to those observed with higher doses of atorvastatin and simvastatin but are less affected by <italic>APOA5</italic> genotype. These findings support the growing recognition that rosuvastatin is a potentially better treatment option for patients with dyslipidemia and/or at high risk of cardiovascular diseases when genetic information is not available. In addition, integrated efforts, such as the NIH Pharmacogenetics Research Network (<xref rid="B15" ref-type="bibr">Giacomini et al., 2007</xref>), should be encouraged in the era of precision medicine to accelerate pharmacogenetics or pharmacogenomics research. Future studies may also need to consider stratifying populations by genetic background and by prescribed statin type.</p></sec><sec><title>Author Contributions</title><p>SH, GL, NX, and JrZ designed the study. SH performed the randomization process and clinical intervention. JL and WW enrolled participants and measured the lipids and apolipoproteins. JZ and GL performed the genotyping analysis. SH, CM, JL, and WW collected and analyzed the data. SH, CM, GL, and JrZ wrote the manuscript.</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was supported by fundings to SH from both the Science Committee Foundation of Huangpu District (HKW201503) and Shanghai Municipal Commission of Health and Family Planning (20174Y0142), Shanghai, China.</p></fn></fn-group><ack><p>We would like to thank Dr. Hao Wu from University of Gothenburg as well as Dr. Bingxiang Xu from Beijing Institute of Genomics for the helpful discussions on the manuscript and data analysis. We also appreciate the great help from Dr. Rosie Perkins for editing our manuscript.</p></ack><sec sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2018.00352/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2018.00352/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Table_2.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Image_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM4"><media xlink:href="Image_2.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arad</surname><given-names>Y.</given-names></name><name><surname>Ramakrishnan</surname><given-names>R.</given-names></name><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name></person-group> (<year>1992</year>). <article-title>Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.</article-title>
<source><italic>Metabolism</italic></source>
<volume>41</volume>
<fpage>487</fpage>&#x02013;<lpage>493</lpage>. <pub-id pub-id-type="doi">10.1016/0026-0495(92)90206-P</pub-id>
<pub-id pub-id-type="pmid">1588827</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshad</surname><given-names>A. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.</article-title>
<source><italic>J. Lipids</italic></source>
<volume>2014</volume>
<issue>875907</issue>. <pub-id pub-id-type="doi">10.1155/2014/875907</pub-id>
<pub-id pub-id-type="pmid">24800084</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>C. M.</given-names></name><name><surname>Bertolami</surname><given-names>M.</given-names></name><name><surname>Hernandez Garcia</surname><given-names>H. R.</given-names></name><name><surname>Nul</surname><given-names>D.</given-names></name><name><surname>Stein</surname><given-names>E. A.</given-names></name><name><surname>Theroux</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapY (MERCURY) II.</article-title>
<source><italic>Am. Heart J.</italic></source>
<fpage>975.e1</fpage>&#x02013;<lpage>979.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2005.12.013</pub-id>
<pub-id pub-id-type="pmid">16644314</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>C. M.</given-names></name><name><surname>Raichlen</surname><given-names>J. S.</given-names></name><name><surname>Cain</surname><given-names>V. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.</article-title>
<source><italic>J. Am. Coll. Cardiol.</italic></source>
<volume>52</volume>
<fpage>626</fpage>&#x02013;<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2008.04.052</pub-id>
<pub-id pub-id-type="pmid">18702965</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>L.</given-names></name><name><surname>Tomlinson</surname><given-names>B.</given-names></name><name><surname>Thomas</surname><given-names>G. N.</given-names></name></person-group> (<year>2003</year>). <article-title>APOA5-1131T &#x0003e; C polymorphism is associated with triglyceride levels in Chinese men.</article-title>
<source><italic>Clin. Genet.</italic></source>
<volume>63</volume>
<fpage>377</fpage>&#x02013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1034/j.1399-0004.2003.00063.x</pub-id>
<pub-id pub-id-type="pmid">12752569</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y.</given-names></name><name><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing.</article-title>
<source><italic>J. R. Stat. Soc. Series B</italic></source>
<volume>57</volume>
<fpage>289</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.2307/2346101</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brautbar</surname><given-names>A.</given-names></name><name><surname>Covarrubias</surname><given-names>D.</given-names></name><name><surname>Belmont</surname><given-names>J.</given-names></name><name><surname>Lara-Garduno</surname><given-names>F.</given-names></name><name><surname>Virani</surname><given-names>S. S.</given-names></name><name><surname>Jones</surname><given-names>P. H.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.</article-title>
<source><italic>Atherosclerosis</italic></source>
<volume>219</volume>
<fpage>737</fpage>&#x02013;<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.08.015</pub-id>
<pub-id pub-id-type="pmid">21889769</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunzell</surname><given-names>J. D.</given-names></name><name><surname>Davidson</surname><given-names>M.</given-names></name><name><surname>Furberg</surname><given-names>C. D.</given-names></name><name><surname>Goldberg</surname><given-names>R. B.</given-names></name><name><surname>Howard</surname><given-names>B. V.</given-names></name><name><surname>Stein</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American diabetes association and the American college of cardiology foundation.</article-title>
<source><italic>J. Am. Coll. Cardiol.</italic></source>
<volume>51</volume>
<fpage>1512</fpage>&#x02013;<lpage>1524</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2008.02.034</pub-id>
<pub-id pub-id-type="pmid">18402913</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caussy</surname><given-names>C.</given-names></name><name><surname>Charriere</surname><given-names>S.</given-names></name><name><surname>Marcais</surname><given-names>C.</given-names></name><name><surname>Di Filippo</surname><given-names>M.</given-names></name><name><surname>Sassolas</surname><given-names>A.</given-names></name><name><surname>Delay</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>An APOA5 3&#x02032; UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.</article-title>
<source><italic>Am. J. Hum. Genet.</italic></source>
<volume>94</volume>
<fpage>129</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2013.12.001</pub-id>
<pub-id pub-id-type="pmid">24387992</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champely</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <source><italic>pwr: Basic Functions for Power Analysis. R package version 1.1-3</italic>.</source> Available at: <ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/package=pwr">http://cran.r-project.org/package=pwr</ext-link></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Association of rs662799 in APOA5 with CAD in Chinese Han population.</article-title>
<source><italic>BMC Cardiovasc. Disord.</italic></source>
<volume>18</volume>:<issue>2</issue>. <pub-id pub-id-type="doi">10.1186/s12872-017-0735-7</pub-id>
<pub-id pub-id-type="pmid">29310573</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><collab>Cholesterol Treatment Trialists (CTT) Collaborators</collab> (<year>2012</year>). <article-title>The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.</article-title>
<source><italic>Lancet</italic></source>
<volume>380</volume>
<fpage>581</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60367-5</pub-id>
<pub-id pub-id-type="pmid">22607822</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Caterina</surname><given-names>R.</given-names></name><name><surname>Talmud</surname><given-names>P. J.</given-names></name><name><surname>Merlini</surname><given-names>P. A.</given-names></name><name><surname>Foco</surname><given-names>L.</given-names></name><name><surname>Pastorino</surname><given-names>R.</given-names></name><name><surname>Altshuler</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Strong association of the APOA5-1131T&#x0003e;C gene variant and early-onset acute myocardial infarction.</article-title>
<source><italic>Atherosclerosis</italic></source>
<volume>214</volume>
<fpage>397</fpage>&#x02013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.11.011</pub-id>
<pub-id pub-id-type="pmid">21130994</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>R.</given-names></name><name><surname>Stitziel</surname><given-names>N. O.</given-names></name><name><surname>Won</surname><given-names>H. H.</given-names></name><name><surname>Jorgensen</surname><given-names>A. B.</given-names></name><name><surname>Duga</surname><given-names>S.</given-names></name><name><surname>Angelica Merlini</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.</article-title>
<source><italic>Nature</italic></source>
<volume>518</volume>
<fpage>102</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1038/nature13917</pub-id>
<pub-id pub-id-type="pmid">25487149</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacomini</surname><given-names>K. M.</given-names></name><name><surname>Brett</surname><given-names>C. M.</given-names></name><name><surname>Altman</surname><given-names>R. B.</given-names></name><name><surname>Benowitz</surname><given-names>N. L.</given-names></name><name><surname>Dolan</surname><given-names>M. E.</given-names></name><name><surname>Flockhart</surname><given-names>D. A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The pharmacogenetics research network: from SNP discovery to clinical drug response.</article-title>
<source><italic>Clin. Pharmacol. Ther.</italic></source>
<volume>81</volume>
<fpage>328</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1038/sj.clpt.6100087</pub-id>
<pub-id pub-id-type="pmid">17339863</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of statins on triglyceride metabolism.</article-title>
<source><italic>Am. J. Cardiol</italic></source>
<volume>81</volume>
<fpage>32B</fpage>&#x02013;<lpage>35B</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9149(98)00035-6</pub-id><pub-id pub-id-type="pmid">9462602</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name><name><surname>Le</surname><given-names>N. A.</given-names></name><name><surname>Short</surname><given-names>M. P.</given-names></name><name><surname>Ramakrishnan</surname><given-names>R.</given-names></name><name><surname>Desnick</surname><given-names>R. J.</given-names></name></person-group> (<year>1987</year>). <article-title>Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>80</volume>
<fpage>1692</fpage>&#x02013;<lpage>1697</lpage>. <pub-id pub-id-type="doi">10.1172/JCI113259</pub-id>
<pub-id pub-id-type="pmid">3680522</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graffelman</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Exploring diallelic genetic markers: the Hardyweinberg package.</article-title>
<source><italic>J. Stat. Softw.</italic></source>
<volume>64</volume>
<fpage>1</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v064.i03</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryn</surname><given-names>S. E.</given-names></name><name><surname>Hegele</surname><given-names>R. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Pharmacogenomics, lipid disorders, and treatment options.</article-title>
<source><italic>Clin. Pharmacol. Ther.</italic></source>
<volume>96</volume>
<fpage>36</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2014.82</pub-id>
<pub-id pub-id-type="pmid">24722394</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guardiola</surname><given-names>M.</given-names></name><name><surname>Cofan</surname><given-names>M.</given-names></name><name><surname>de Castro-Oros</surname><given-names>I.</given-names></name><name><surname>Cenarro</surname><given-names>A.</given-names></name><name><surname>Plana</surname><given-names>N.</given-names></name><name><surname>Talmud</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.</article-title>
<source><italic>Atherosclerosis</italic></source>
<volume>240</volume>
<fpage>98</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.03.008</pub-id>
<pub-id pub-id-type="pmid">25770687</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guardiola</surname><given-names>M.</given-names></name><name><surname>Ribalta</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Update on APOA5 genetics: toward a better understanding of its physiological impact.</article-title>
<source><italic>Curr. Atheroscler Rep.</italic></source>
<volume>19</volume>:<issue>30</issue>. <pub-id pub-id-type="doi">10.1007/s11883-017-0665-y</pub-id>
<pub-id pub-id-type="pmid">28500476</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Dorajoo</surname><given-names>R.</given-names></name><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Khor</surname><given-names>C. C.</given-names></name><name><surname>Sim</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>7</volume>:<issue>17921</issue>. <pub-id pub-id-type="doi">10.1038/s41598-017-18214-z</pub-id>
<pub-id pub-id-type="pmid">29263402</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegele</surname><given-names>R. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Plasma lipoproteins: genetic influences and clinical implications.</article-title>
<source><italic>Nat. Rev. Genet.</italic></source>
<volume>10</volume>
<fpage>109</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1038/nrg2481</pub-id>
<pub-id pub-id-type="pmid">19139765</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henneman</surname><given-names>P.</given-names></name><name><surname>Schaap</surname><given-names>F. G.</given-names></name><name><surname>Havekes</surname><given-names>L. M.</given-names></name><name><surname>Rensen</surname><given-names>P. C.</given-names></name><name><surname>Frants</surname><given-names>R. R.</given-names></name><name><surname>van Tol</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.</article-title>
<source><italic>Atherosclerosis</italic></source>
<volume>193</volume>
<fpage>129</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.05.030</pub-id>
<pub-id pub-id-type="pmid">16777114</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>J. A.</given-names></name><name><surname>Adamkova</surname><given-names>V.</given-names></name><name><surname>Prusikova</surname><given-names>M.</given-names></name><name><surname>Snejdrlova</surname><given-names>M.</given-names></name><name><surname>Hirschfeldova</surname><given-names>K.</given-names></name><name><surname>Lanska</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Impact of apolipoprotein A5 variants on statin treatment efficacy.</article-title>
<source><italic>Pharmacogenomics</italic></source>
<volume>10</volume>
<fpage>945</fpage>&#x02013;<lpage>950</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.09.17</pub-id>
<pub-id pub-id-type="pmid">19530961</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>J. A.</given-names></name><name><surname>Lanska</surname><given-names>V.</given-names></name><name><surname>Skodova</surname><given-names>Z.</given-names></name><name><surname>Adamkova</surname><given-names>V.</given-names></name><name><surname>Poledne</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels.</article-title>
<source><italic>Eur. J. Hum. Genet.</italic></source>
<volume>16</volume>
<fpage>135</fpage>&#x02013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5201941</pub-id>
<pub-id pub-id-type="pmid">17957227</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>J. A.</given-names></name><name><surname>Skodova</surname><given-names>Z.</given-names></name><name><surname>Adamkova</surname><given-names>V.</given-names></name><name><surname>Lanska</surname><given-names>V.</given-names></name><name><surname>Poledne</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). <article-title>The influence of APOAV polymorphisms (T-1131&#x0003e;C and S19&#x0003e;W) on plasma triglyceride levels and risk of myocardial infarction.</article-title>
<source><italic>Clin. Genet.</italic></source>
<volume>65</volume>
<fpage>126</fpage>&#x02013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1111/j.0009-9163.2004.00199.x</pub-id>
<pub-id pub-id-type="pmid">14984471</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>D. J.</given-names></name><name><surname>Kendall</surname><given-names>C. W.</given-names></name><name><surname>Marchie</surname><given-names>A.</given-names></name><name><surname>Faulkner</surname><given-names>D. A.</given-names></name><name><surname>Wong</surname><given-names>J. M.</given-names></name><name><surname>de Souza</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants.</article-title>
<source><italic>Am. J. Clin. Nutr.</italic></source>
<volume>81</volume>
<fpage>380</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn.81.2.380</pub-id>
<pub-id pub-id-type="pmid">15699225</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C. Q.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Cheung</surname><given-names>B. M.</given-names></name><name><surname>Lam</surname><given-names>T. H.</given-names></name><name><surname>Lin</surname><given-names>J. M.</given-names></name><name><surname>Li Jin</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese.</article-title>
<source><italic>Eur. J. Hum. Genet.</italic></source>
<volume>18</volume>
<fpage>1255</fpage>&#x02013;<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2010.93</pub-id>
<pub-id pub-id-type="pmid">20571505</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaddurah-Daouk</surname><given-names>R.</given-names></name><name><surname>Baillie</surname><given-names>R. A.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>Z. B.</given-names></name><name><surname>Wiest</surname><given-names>M. M.</given-names></name><name><surname>Nguyen</surname><given-names>U. T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Enteric microbiome metabolites correlate with response to simvastatin treatment.</article-title>
<source><italic>PLoS One</italic></source>
<volume>6</volume>:<issue>e25482</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0025482</pub-id>
<pub-id pub-id-type="pmid">22022402</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlson</surname><given-names>B. W.</given-names></name><name><surname>Palmer</surname><given-names>M. K.</given-names></name><name><surname>Nicholls</surname><given-names>S. J.</given-names></name><name><surname>Lundman</surname><given-names>P.</given-names></name><name><surname>Barter</surname><given-names>P. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.</article-title>
<source><italic>Eur. J. Prev. Cardiol.</italic></source>
<volume>23</volume>
<fpage>744</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1177/2047487315598710</pub-id>
<pub-id pub-id-type="pmid">26246463</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>O. Y.</given-names></name><name><surname>Moon</surname><given-names>J.</given-names></name><name><surname>Jo</surname><given-names>G.</given-names></name><name><surname>Kwak</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><name><surname>Shin</surname><given-names>M. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Apolipoprotein A5 3&#x02019;-UTR variants and cardiometabolic traits in Koreans: results from the Korean genome and epidemiology study and the Korea National Health and Nutrition Examination Survey.</article-title>
<source><italic>Nutr. Res. Pract.</italic></source>
<volume>12</volume>
<fpage>61</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.4162/nrp.2018.12.1.61</pub-id>
<pub-id pub-id-type="pmid">29399298</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kivisto</surname><given-names>K. T.</given-names></name><name><surname>Niemi</surname><given-names>M.</given-names></name><name><surname>Schaeffeler</surname><given-names>E.</given-names></name><name><surname>Pitkala</surname><given-names>K.</given-names></name><name><surname>Tilvis</surname><given-names>R.</given-names></name><name><surname>Fromm</surname><given-names>M. F.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Lipid-lowering response to statins is affected by CYP3A5 polymorphism.</article-title>
<source><italic>Pharmacogenetics</italic></source>
<volume>14</volume>
<fpage>523</fpage>&#x02013;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1097/01.fpc.0000114762.78957.a5</pub-id>
<pub-id pub-id-type="pmid">15284534</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C. Q.</given-names></name><name><surname>Demissie</surname><given-names>S.</given-names></name><name><surname>Cupples</surname><given-names>L. A.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Adiconis</surname><given-names>X.</given-names></name><name><surname>Parnell</surname><given-names>L. D.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study.</article-title>
<source><italic>J. Lipid Res.</italic></source>
<volume>45</volume>
<fpage>2096</fpage>&#x02013;<lpage>2105</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M400192-JLR200</pub-id>
<pub-id pub-id-type="pmid">15342688</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>H. H.</given-names></name><name><surname>Choi</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>O. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Increased risk of obesity related to total energy intake with the APOA5-1131T&#x0003e;C polymorphism in Korean premenopausal women.</article-title>
<source><italic>Nutr. Res.</italic></source>
<volume>34</volume>
<fpage>827</fpage>&#x02013;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1016/j.nutres.2014.08.018</pub-id>
<pub-id pub-id-type="pmid">25263629</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Nilsson-Ehle</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name></person-group> (<year>2009</year>). <article-title>Genotyping of single nucleotide polymorphisms using base-quenched probe: a method does not invariably depend on the deoxyguanosine nucleotide.</article-title>
<source><italic>Anal. Biochem.</italic></source>
<volume>386</volume>
<fpage>161</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2008.11.032</pub-id>
<pub-id pub-id-type="pmid">19109921</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangravite</surname><given-names>L. M.</given-names></name><name><surname>Thorn</surname><given-names>C. F.</given-names></name><name><surname>Krauss</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Clinical implications of pharmacogenomics of statin treatment.</article-title>
<source><italic>Pharmacogenomics J.</italic></source>
<volume>6</volume>
<fpage>360</fpage>&#x02013;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500384</pub-id>
<pub-id pub-id-type="pmid">16550210</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P. D.</given-names></name><name><surname>Warwick</surname><given-names>M. J.</given-names></name><name><surname>Dane</surname><given-names>A. L.</given-names></name><name><surname>Hill</surname><given-names>S. J.</given-names></name><name><surname>Giles</surname><given-names>P. B.</given-names></name><name><surname>Phillips</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.</article-title>
<source><italic>Clin. Ther.</italic></source>
<volume>25</volume>
<fpage>2822</fpage>&#x02013;<lpage>2835</lpage>. <pub-id pub-id-type="doi">10.1016/S0149-2918(03)80336-3</pub-id><pub-id pub-id-type="pmid">14693307</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>J. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Efficacy and safety of rosuvastatin in treatment of dyslipidemia.</article-title>
<source><italic>Am. J. Health Syst. Pharm.</italic></source>
<volume>62</volume>
<fpage>1033</fpage>&#x02013;<lpage>1047</lpage>.<pub-id pub-id-type="pmid">15901588</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTaggart</surname><given-names>F.</given-names></name></person-group> (<year>2003</year>). <article-title>Comparative pharmacology of rosuvastatin.</article-title>
<source><italic>Atheroscler Suppl.</italic></source>
<volume>4</volume>
<fpage>9</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/S1567-5688(03)00004-7</pub-id><pub-id pub-id-type="pmid">12714032</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>S. K.</given-names></name><name><surname>Lookene</surname><given-names>A.</given-names></name><name><surname>Beckstead</surname><given-names>J. A.</given-names></name><name><surname>Gliemann</surname><given-names>J.</given-names></name><name><surname>Ryan</surname><given-names>R. O.</given-names></name><name><surname>Olivecrona</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family.</article-title>
<source><italic>Biochemistry</italic></source>
<volume>46</volume>
<fpage>3896</fpage>&#x02013;<lpage>3904</lpage>. <pub-id pub-id-type="doi">10.1021/bi7000533</pub-id>
<pub-id pub-id-type="pmid">17326667</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>S. E.</given-names></name><name><surname>Schrodi</surname><given-names>S. J.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Brilliant</surname><given-names>M. H.</given-names></name><name><surname>Virani</surname><given-names>S. S.</given-names></name><name><surname>Brautbar</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Differential lipid response to statins is associated with variants in the BUD13-APOA5 gene region.</article-title>
<source><italic>J. Cardiovasc. Pharmacol.</italic></source>
<volume>66</volume>
<fpage>183</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1097/FJC.0000000000000261</pub-id>
<pub-id pub-id-type="pmid">25900265</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouatou</surname><given-names>S.</given-names></name><name><surname>Ajjemami</surname><given-names>M.</given-names></name><name><surname>Charoute</surname><given-names>H.</given-names></name><name><surname>Sefri</surname><given-names>H.</given-names></name><name><surname>Ghalim</surname><given-names>N.</given-names></name><name><surname>Rhaissi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Association of APOA5 rs662799 and rs3135506 polymorphisms with arterial hypertension in Moroccan patients.</article-title>
<source><italic>Lipids Health Dis.</italic></source>
<volume>13</volume>
<fpage>60</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1186/1476-511X-13-60</pub-id>
<pub-id pub-id-type="pmid">24684850</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>M. K.</given-names></name><name><surname>Nicholls</surname><given-names>S. J.</given-names></name><name><surname>Lundman</surname><given-names>P.</given-names></name><name><surname>Barter</surname><given-names>P. J.</given-names></name><name><surname>Karlson</surname><given-names>B. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.</article-title>
<source><italic>Eur. J. Prev. Cardiol.</italic></source>
<volume>20</volume>
<fpage>1080</fpage>&#x02013;<lpage>1087</lpage>. <pub-id pub-id-type="doi">10.1177/2047487313489875</pub-id>
<pub-id pub-id-type="pmid">23644489</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennacchio</surname><given-names>L. A.</given-names></name><name><surname>Olivier</surname><given-names>M.</given-names></name><name><surname>Hubacek</surname><given-names>J. A.</given-names></name><name><surname>Cohen</surname><given-names>J. C.</given-names></name><name><surname>Cox</surname><given-names>D. R.</given-names></name><name><surname>Fruchart</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.</article-title>
<source><italic>Science</italic></source>
<volume>294</volume>
<fpage>169</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1126/science.1064852</pub-id>
<pub-id pub-id-type="pmid">11588264</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postmus</surname><given-names>I.</given-names></name><name><surname>Trompet</surname><given-names>S.</given-names></name><name><surname>Deshmukh</surname><given-names>H. A.</given-names></name><name><surname>Barnes</surname><given-names>M. R.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Warren</surname><given-names>H. R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>5</volume>:<issue>5068</issue>. <pub-id pub-id-type="doi">10.1038/ncomms6068</pub-id>
<pub-id pub-id-type="pmid">25350695</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="book"><collab>R Development Core Team</collab> (<year>2015</year>). <source><italic>R: A Language and Environment for Statistical Computing</italic>.</source>
<publisher-loc>Vienna</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>.</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P. M.</given-names></name><name><surname>Mora</surname><given-names>S.</given-names></name><name><surname>Rose</surname><given-names>L.</given-names></name><name><surname>Group</surname><given-names>J. T. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.</article-title>
<source><italic>Eur. Heart J.</italic></source>
<volume>37</volume>
<fpage>1373</fpage>&#x02013;<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehw046</pub-id>
<pub-id pub-id-type="pmid">26916794</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schachter</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.</article-title>
<source><italic>Fundam. Clin. Pharmacol.</italic></source>
<volume>19</volume>
<fpage>117</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-8206.2004.00299.x</pub-id>
<pub-id pub-id-type="pmid">15660968</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>L. J.</given-names></name><name><surname>Curran</surname><given-names>M. P.</given-names></name><name><surname>Figgitt</surname><given-names>D. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Rosuvastatin: a review of its use in the management of dyslipidemia.</article-title>
<source><italic>Am. J. Cardiovasc. Drugs</italic></source>
<volume>4</volume>
<fpage>117</fpage>&#x02013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.2165/00129784-200404020-00005</pub-id><pub-id pub-id-type="pmid">15049723</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>K. Y.</given-names></name><name><surname>Son</surname><given-names>H. Y.</given-names></name><name><surname>Chae</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>J.</given-names></name><name><surname>Jang</surname><given-names>S.</given-names></name><name><surname>Yun</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men.</article-title>
<source><italic>Lipids Health Dis.</italic></source>
<volume>14</volume>
<fpage>105</fpage>&#x02013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1186/s12944-015-0111-5</pub-id>
<pub-id pub-id-type="pmid">26365620</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>N. J.</given-names></name><name><surname>Robinson</surname><given-names>J. G.</given-names></name><name><surname>Lichtenstein</surname><given-names>A. H.</given-names></name><name><surname>Bairey Merz</surname><given-names>C. N.</given-names></name><name><surname>Blum</surname><given-names>C. B.</given-names></name><name><surname>Eckel</surname><given-names>R. H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
<source><italic>Circulation</italic></source>
<volume>129(25 Suppl. 2)</volume>, <fpage>S1</fpage>&#x02013;<lpage>S45</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.0000437738.63853.7a</pub-id>
<pub-id pub-id-type="pmid">24222016</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talmud</surname><given-names>P. J.</given-names></name><name><surname>Cooper</surname><given-names>J. A.</given-names></name><name><surname>Hattori</surname><given-names>H.</given-names></name><name><surname>Miller</surname><given-names>I. P.</given-names></name><name><surname>Miller</surname><given-names>G. J.</given-names></name><name><surname>Humphries</surname><given-names>S. E.</given-names></name></person-group> (<year>2006</year>). <article-title>The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.</article-title>
<source><italic>Diabetologia</italic></source>
<volume>49</volume>
<fpage>2337</fpage>&#x02013;<lpage>2340</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-006-0387-0</pub-id>
<pub-id pub-id-type="pmid">16917759</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talmud</surname><given-names>P. J.</given-names></name><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Taskinen</surname><given-names>M. R.</given-names></name><name><surname>Frick</surname><given-names>M. H.</given-names></name><name><surname>Nieminen</surname><given-names>M. S.</given-names></name><name><surname>Kesaniemi</surname><given-names>Y. A.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.</article-title>
<source><italic>J. Lipid Res.</italic></source>
<volume>45</volume>
<fpage>750</fpage>&#x02013;<lpage>756</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M300458-JLR200</pub-id>
<pub-id pub-id-type="pmid">14729863</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vliet</surname><given-names>H. N.</given-names></name><name><surname>Sammels</surname><given-names>M. G.</given-names></name><name><surname>Leegwater</surname><given-names>A. C.</given-names></name><name><surname>Levels</surname><given-names>J. H.</given-names></name><name><surname>Reitsma</surname><given-names>P. H.</given-names></name><name><surname>Boers</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>276</volume>
<fpage>44512</fpage>&#x02013;<lpage>44520</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M106888200</pub-id>
<pub-id pub-id-type="pmid">11577099</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list id="DL1"><def-item><term>ApoA5</term><def><p>apolipoprotein A5</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>FFAs</term><def><p>free fatty acids</p></def></def-item><def-item><term>HDLc</term><def><p>high-density lipoprotein cholesterol</p></def></def-item><def-item><term>LDLc</term><def><p>low-density lipoprotein cholesterol</p></def></def-item><def-item><term>Lp(a)</term><def><p>lipoprotein(a)</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item><def-item><term>T2D</term><def><p>type 2 diabetes</p></def></def-item><def-item><term>Tc</term><def><p>total cholesterol</p></def></def-item><def-item><term>Tg</term><def><p>triglycerides.</p></def></def-item></def-list></glossary></back></article>